BSN Tracker

linaclotide

Brand: Linzess

⚠ BBW Prototype Drug
Drug Class: guanylate cyclase-C agonist
Drug Family: GI agent
Subclass: GC-C agonist secretagogue
Organ Systems: gastrointestinal

Mechanism of Action

Activates GC-C receptors on intestinal luminal surface, increasing intracellular cyclic GMP (cGMP). Elevated cGMP activates CFTR chloride channels to secrete chloride and bicarbonate into the intestinal lumen, followed by water, promoting secretion, accelerated transit, and reduced visceral pain via decreased nociceptor sensitivity.

guanylate cyclase-C (GC-C) receptors on intestinal epithelium

Indications

  • chronic idiopathic constipation (CIC)
  • irritable bowel syndrome with constipation (IBS-C)

Contraindications

  • children under 6 years (risk of serious dehydration and death)
  • known or suspected mechanical GI obstruction

Adverse Effects

Common

  • diarrhea (most common; up to 20%)
  • abdominal pain
  • flatulence
  • headache

Serious

  • severe diarrhea leading to dehydration
  • electrolyte abnormalities

Pharmacokinetics (ADME)

Absorption minimal systemic absorption; acts locally in GI lumen
Distribution negligible systemic distribution
Metabolism proteolytic cleavage within GI tract to active metabolite MM-419447
Excretion fecal
Half-life not meaningful (local action)
Onset 1–2 weeks
Peak 2–4 weeks
Duration continuous dosing
Protein Binding negligible
Vd negligible

Nursing Considerations

  1. Administer on an empty stomach at least 30 minutes before the first meal of the day for optimal efficacy.
  2. Counsel patient that diarrhea is the most common reason for discontinuation; dose should be withheld and prescriber notified if severe diarrhea with dehydration occurs.
  3. Confirm there are no children under 6 years in the household (safety cap required; tablets should never be given to children <6).
  4. Separate IBS-C dose (290 mcg) from CIC dose (145 mcg or 72 mcg); know which indication is being treated.

Clinical Pearls

  • Linaclotide's analgesic effect on visceral pain in IBS-C is mediated through intracellular cGMP activating submucosal afferent fibers — this dual action (pro-secretory and analgesic) distinguishes it from simple laxatives.
  • Differs from lubiprostone in mechanism: linaclotide activates GC-C receptors to trigger CFTR-mediated secretion, while lubiprostone activates ClC-2 chloride channels directly.

Safety Profile

Pregnancy avoid
Lactation generally-safe
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Chronic Idiopathic Constipation (CIC) Guanylate Cyclase-C Agonist Irritable Bowel Syndrome With Constipation (IBS-C)
← Back to Medications